Other Events.

On April 13, 2017, Invacare Corporation (the “company”) received notification from the United States Food and Drug Administration (FDA) that it accepted the recent second certification report by the company’s third-party expert relating to design control requirements. The company may now resume design activities at the Corporate and Taylor Street manufacturing facilities in Elyria, Ohio. The company is pleased to have achieved this milestone and believes it reflects the company’s continued emphasis on building a quality culture as part of its long-term transformation.

For more information about the consent decree, refer to the company’s Form 10-K and 10-Q filings with the Securities and Exchange Commission (SEC).

About INVACARE CORPORATION (NYSE:IVC)

Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific. The Company manufactures and distributes three product categories: mobility and seating, lifestyle and respiratory therapy. It provides medical device solutions for congenital (cerebral palsy, muscular dystrophy and spina bifida), acquired (stroke, spinal cord injury, traumatic brain injury, post-acute recovery and pressure ulcers) and degenerative (amyotrophic lateral sclerosis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly and bariatric) ailments. The Company sells its products to home medical equipment providers with retail and e-commerce channels, residential living operators, distributors and government health services.

INVACARE CORPORATION (NYSE:IVC) Recent Trading Information

INVACARE CORPORATION (NYSE:IVC) closed its last trading session down -0.20 at 10.50 with 166,283 shares trading hands.